TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06171750: Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Sponsor: Ankyra Therapeutics, Inc · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 97 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06171750 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06171750 Rescue Dossier →